Checkpoint Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Checkpoint Therapeutics is forecast to grow earnings and revenue by 44.4% and 205.6% per annum respectively while EPS is expected to grow by 46.8% per annum.

Anahtar bilgiler

44.4%

Kazanç büyüme oranı

46.8%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.1%
Gelir büyüme oranı	205.6%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	16 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Sep 20

Checkpoint: Strong Data, But Comes With Risks

Sep 08

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Aug 12

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

May 18

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Apr 18

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

Feb 15

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Jan 28

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Nov 26

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Oct 30

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Jul 17

It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year

Jun 02

The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It

Mar 11

Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?

Feb 06

Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?

Jan 27

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:CKPT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	52	-22	N/A	N/A	2
12/31/2024	0	-31	N/A	N/A	3
6/30/2024	0	-42	-34	-34	N/A
3/31/2024	0	-52	-40	-40	N/A
12/31/2023	0	-52	-48	-48	N/A
9/30/2023	0	-54	-56	-56	N/A
6/30/2023	0	-59	-53	-53	N/A
3/31/2023	0	-56	-52	-52	N/A
12/31/2022	0	-63	-58	-58	N/A
9/30/2022	0	-71	-52	-52	N/A
6/30/2022	0	-72	-47	-47	N/A
3/31/2022	0	-67	-41	-41	N/A
12/31/2021	0	-57	-26	-26	N/A
9/30/2021	0	-37	-22	-22	N/A
6/30/2021	0	-31	-20	-20	N/A
3/31/2021	0	-26	-17	-17	N/A
12/31/2020	1	-23	-17	-17	N/A
9/30/2020	1	-22	-16	-16	N/A
6/30/2020	1	-22	-15	-15	N/A
3/31/2020	2	-22	-18	-18	N/A
12/31/2019	2	-25	-21	-21	N/A
9/30/2019	5	-28	-24	-24	N/A
6/30/2019	4	-32	-27	-27	N/A
3/31/2019	4	-33	-29	-29	N/A
12/31/2018	4	-36	-26	-26	N/A
9/30/2018	1	-31	-22	-22	N/A
6/30/2018	1	-27	-20	-20	N/A
3/31/2018	1	-27	N/A	-18	N/A
12/31/2017	2	-23	N/A	-15	N/A
9/30/2017	2	-25	N/A	-15	N/A
6/30/2017	2	-24	N/A	-14	N/A
3/31/2017	3	-23	N/A	-11	N/A
12/31/2016	3	-22	N/A	-10	N/A
9/30/2016	2	-22	N/A	-7	N/A
6/30/2016	2	-21	N/A	-7	N/A
3/31/2016	0	-16	N/A	-5	N/A
12/31/2015	1	-14	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CKPT is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: CKPT is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: CKPT is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: CKPT's revenue (205.6% per year) is forecast to grow faster than the US market (8.9% per year).

Yüksek Büyüme Geliri: CKPT's revenue (205.6% per year) is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if CKPT's Return on Equity is forecast to be high in 3 years time

Checkpoint Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 11%

Price target increased by 19% to US$21.67

No longer forecast to breakeven

Consensus revenue estimates increase by 25%, EPS downgraded

Consensus revenue estimates increase by 19%

Consensus revenue estimates increase by 41%

Recent updates

Checkpoint Therapeutics, Inc. Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Consensus revenue estimates increase by 11%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Checkpoint Therapeutics, Inc Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Price target increased by 19% to US$21.67

Checkpoint Therapeutics, Inc. announced a financing transaction

Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.000001 million.

President recently sold US$50k worth of stock

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

No longer forecast to breakeven

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)

Checkpoint Therapeutics, Inc., Annual General Meeting, May 13, 2024

Insufficient new directors

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director

Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule

Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule

New major risk - Financial position

New major risk - Share price stability

Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000001 million.

Checkpoint Therapeutics, Inc. Announces Board Changes, Effective January 31, 2024

Consensus revenue estimates increase by 25%, EPS downgraded

U.S. Food and Drug Administration Issues Complete Response Letter for Checkpoint Therapeutics, Inc.'s Cosibelimab Solely Due to Inspection Findings At Third-Party Manufacturer

Consensus revenue estimates increase by 19%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

First quarter 2023 earnings released: US$0.89 loss per share (vs US$1.98 loss in 1Q 2022)

Consensus revenue estimates increase by 41%

Price target decreased by 42% to US$33.50

Consensus revenue estimates decrease by 78%, EPS upgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$103

Checkpoint Therapeutics, Inc. Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Consensus forecasts updated

Forecast to breakeven in 2024

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 3Q 2021)

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Checkpoint: Strong Data, But Comes With Risks

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Price target decreased to US$17.60

Checkpoint Therapeutics, Inc. Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Consensus forecasts updated

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Checkpoint Therapeutics Inc. Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Checkpoint Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

CFO, Corporate Secretary & Treasurer recently sold US$72k worth of stock

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

CFO, Corporate Secretary & Treasurer recently sold US$93k worth of stock

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Forecast to breakeven in 2024

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.087 loss in 3Q 2020)

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.09 loss in 2Q 2020)

Consensus revenue estimates fall to US$359.0k